Vikram Mohan serves as the Marketing Director for Oncology International at Regeneron, where he leverages his extensive cross-functional international experience to drive innovative marketing strategies and enhance commercial operations. With a strong foundation in pharmaceutical sciences, Vikram is adept at navigating the complexities of the...
Vikram Mohan serves as the Marketing Director for Oncology International at Regeneron, where he leverages his extensive cross-functional international experience to drive innovative marketing strategies and enhance commercial operations. With a strong foundation in pharmaceutical sciences, Vikram is adept at navigating the complexities of the oncology landscape, ensuring that Regeneron’s portfolio not only meets but exceeds market expectations. His leadership is pivotal in the rollout and scale-up of Omni-Channel marketing initiatives across Europe, Japan, and Canada, where he is responsible for creating a best-in-class sales and marketing ecosystem.
Vikram's approach is characterized by a modular content strategy that aligns global objectives with local market needs, enabling tailored messaging that resonates with diverse audiences. He leads a dynamic team of marketing strategists, creative designers, data analysts, and Mar Tech subject matter experts, fostering a collaborative environment that drives innovation and efficiency. His expertise in B2B marketing and marketing communications allows him to effectively engage stakeholders and accelerate revenue growth within the oncology portfolio.
Key projects under Vikram's direction include the implementation of advanced lead generation techniques and mobile marketing strategies that enhance customer engagement and streamline the user experience. His commitment to program management and cross-functional team leadership ensures that all initiatives are executed seamlessly, resulting in measurable business outcomes. As a proven business leader, Vikram Mohan continues to shape the future of oncology marketing at Regeneron, positioning the company as a frontrunner in the pharmaceutical industry.
